Cogent Biosciences, Inc. (COGT) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Cogent Biosciences, Inc. Do?
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Cogent Biosciences, Inc. (COGT) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Andrew R. Robbins and employs approximately 80 people. With a market capitalization of $5.7B, COGT is one of the notable companies in the Healthcare sector.
Cogent Biosciences, Inc. (COGT) Stock Rating — Reduce (April 2026)
As of April 2026, Cogent Biosciences, Inc. receives a Reduce rating with a composite score of 36.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.COGT ranks #2,104 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cogent Biosciences, Inc. ranks #236 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
COGT Stock Price and 52-Week Range
Cogent Biosciences, Inc. (COGT) currently trades at $36.37. The stock lost $0.98 (2.6%) in the most recent trading session. The 52-week high for COGT is $43.73, which means the stock is currently trading -16.8% from its annual peak. The 52-week low is $3.72, putting the stock 877.7% above its annual trough. Recent trading volume was 1.5M shares, reflecting moderate market activity.
Is COGT Overvalued or Undervalued? — Valuation Analysis
Cogent Biosciences, Inc. (COGT) carries a value factor score of 27/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 9.09x, versus the sector average of 2.75x.
At current multiples, Cogent Biosciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
Cogent Biosciences, Inc. Profitability — ROE, Margins, and Quality Score
Cogent Biosciences, Inc. (COGT) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -46.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -31.7% versus the sector average of -33.1%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
COGT Debt, Balance Sheet, and Financial Health
Cogent Biosciences, Inc. has a debt-to-equity ratio of 35.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 14.23x, indicating strong short-term liquidity. Total debt on the balance sheet is $223M. Cash and equivalents stand at $125M.
COGT has a beta of 1.95, meaning it is more volatile than the broader market — a $10,000 investment in COGT would be expected to move 94.7% more than the S&P 500 on any given day. The stability factor score for Cogent Biosciences, Inc. is 20/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Cogent Biosciences, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Cogent Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.16. Net income for the quarter was $-297M. Operating income came in at $-309M.
In FY 2025, Cogent Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.16. Net income for the quarter was $-329M. Operating income came in at $-333M.
In Q3 2025, Cogent Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.50. Net income for the quarter was $-81M. Operating income came in at $-83M.
In Q2 2025, Cogent Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.53. Net income for the quarter was $-74M. Operating income came in at $-76M.
Over the past 8 quarters, Cogent Biosciences, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing COGT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
COGT Dividend Yield and Income Analysis
Cogent Biosciences, Inc. (COGT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
COGT Momentum and Technical Analysis Profile
Cogent Biosciences, Inc. (COGT) has a momentum factor score of 70/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 41/100 reflects moderate short selling activity.
COGT vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Cogent Biosciences, Inc. (COGT) ranks #236 out of 838 stocks based on the Blank Capital composite score. This places COGT in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing COGT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full COGT vs S&P 500 (SPY) comparison to assess how Cogent Biosciences, Inc. stacks up against the broader market across all factor dimensions.
COGT Next Earnings Date
No upcoming earnings date has been announced for Cogent Biosciences, Inc. (COGT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy COGT? — Investment Thesis Summary
The quantitative profile for Cogent Biosciences, Inc. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 27/100 indicates premium valuation. Price momentum is positive at 70/100, suggesting the trend favors buyers. High volatility (stability score 20/100) increases portfolio risk.
In summary, Cogent Biosciences, Inc. (COGT) earns a Reduce rating with a composite score of 36.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on COGT stock.
Related Resources for COGT Investors
Explore more research and tools: COGT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare COGT head-to-head with peers: COGT vs AZN, COGT vs SLGL, COGT vs VMD.